A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Nirsevimab, a Monoclonal Antibody With Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm and Term Infants in China
Latest Information Update: 18 Mar 2024
Price :
$35 *
At a glance
- Drugs Nirsevimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Registrational; Therapeutic Use
- Acronyms CHIMES
- Sponsors AstraZeneca; AstraZeneca AB
- 11 Apr 2023 Planned End Date changed from 19 Dec 2025 to 28 Nov 2025.
- 11 Apr 2023 Planned primary completion date changed from 23 May 2025 to 2 May 2025.
- 18 Feb 2022 Planned End Date changed from 16 Dec 2025 to 19 Dec 2025.